Cleveland, Ohio (PRWEB) April 09, 2014
Diasome Pharmaceuticals, Inc. (http://www.diasome.com) has announced that Frank McCaney, CEO of Corpak MedSystems, Inc., and Thomas McDonald, founder and CEO of McDonald Partners LLC, have joined its board of directors. Mr. McCaney’s career includes serving in senior management positions at Thermo Electron Corporation and Viasys Healthcare, where he played a lead role in spinning Viasys out of Thermo Electron. In addition, Mr. McCaney served as Founder and CEO of Nitric BioTherapuetics, Inc., a venture-backed life sciences company focused on developing new therapies for infectious diseases. Mr. McDonald brings more than thirty years of experience in the finance industry to the Company’s board, and in addition to his responsibilities at McDonald Partners, he also serves as the Chairman of the Board of Trustees of the MetroHealth Medical Center, an affiliate of the Case Western Reserve University School of Medicine in Cleveland, Ohio.
“We are very pleased that Tom and Frank have joined the Company’s board. Their experience in the financial and life sciences communities, along with their demonstrated interest in improving healthcare bring important expertise and perspective to our team,” said Diasome’s Chairman, Richard Caruso, PhD.
“I am delighted to participate as a member of Diasome’s board,” said Mr. McDonald. “This company represents some of the most innovative technology solutions in the global diabetes pipeline, and I look forward to working closely with Diasome’s board and management team to further the company’s mission.” Mr. McCaney also stated, “Diasome’s technologies for metabolic diseases are focused on addressing the need for hepatic specific therapies, a major unmet need that I believe can be significantly improved by the HDV platform for drug delivery. I am looking forward to seeing Diasome advance its therapies through the clinic.”
About Diasome Pharmaceuticals, Inc.
Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin replacement, and hepatic (liver) glucose metabolism, the Company’s pipeline includes multiple injected and oral formulations of liver targeted insulins for both Type 1 and Type 2 diabetic patients that are Phase 3 ready. In addition, Diasome is developing a first-in-class oral compound for the Type 2 diabetes population that is based upon new insights into normal glucose metabolism and a novel mechanism of action, along with a nanotechnology-based oral compound that may have a significant impact in treating obesity.
Diasome’s technology platform is based on the use of its proprietary Hepatocyte Directed Vesicle, or HDV, nanotechnology to deliver a wide range of critically necessary hormones and drugs to the liver, the body’s primary site of glucose storage. It is generally recognized by diabetologists that the currently available forms of injected insulin used by all Type 1 diabetic patients and a significant percentage of people with Type 2 diabetes do not function in the body in the same way as naturally produced insulin. Because insulin tells the body when and how to store glucose, the ideal insulin therapy would function as closely to normal insulin as possible. Diasome’s HDV system is designed to fundamentally improve the way in which insulin works in people with diabetes by, for the first time, enabling much greater amounts of injected insulin to reach hepatocytes, the liver’s glucose storing cells.